2,4-diethoxycarbonyl-5-hydroxy-5-methyl-3-(3,4-methylenedioxyphenyl)cyclohexan-1-one | 6286-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 2,4-diethoxycarbonyl-5-hydroxy-5-methyl-3-(3,4-methylenedioxyphenyl)cyclohexan-1-one
• 英文别名: 2-benzo[1,3]dioxol-5-yl-4-hydroxy-4-methyl-6-oxo-cyclohexane-1,3-dicarboxylic acid diethyl ester；2-Benzo[1,3]dioxol-5-yl-4-hydroxy-4-methyl-6-oxo-cyclohexan-1,3-dicarbonsaeure-diaethylester；Diethyl 2-(1,3-benzodioxol-5-yl)-4-hydroxy-4-methyl-6-oxocyclohexane-1,3-dicarboxylate
• CAS: 6286-69-7
• 化学式: C₂₀H₂₄O₈
• mdl: MFCD00717864
• 分子量: 392.406
• InChiKey: HSXXKYCRIUTPKT-UHFFFAOYSA-N

物化性质

• 沸点：
  525.9±50.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2,4-diethoxycarbonyl-5-hydroxy-5-methyl-3-(3,4-methylenedioxyphenyl)cyclohexan-1-one 在 sodium hydroxide 、 乙酸酐 作用下， 以 乙醇 为溶剂， 生成 3-<3,4-Methylendioxy-phenyl>-glutarsaeure-anhydrid
  参考文献：
  名称：

  Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists

  摘要：

  We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.045
• 作为产物：
  描述：

  胡椒醛 、 乙酰乙酸乙酯 在 哌啶 作用下， 反应 70.0h， 以82%的产率得到2,4-diethoxycarbonyl-5-hydroxy-5-methyl-3-(3,4-methylenedioxyphenyl)cyclohexan-1-one
  参考文献：
  名称：

  Lignanes。18.总体结构和共性确认书

  摘要：

  大cetrooniconic acid 1具有非常优异的结构，因为它可能是唯一的内酯环被芳基，亚芳基和羧基取代的γ-丁内酯木脂素。该木脂素的结构通过外消旋的全合成得到证实，该合成涉及作为关键步骤的3-芳基戊二酸酯8与对茴香醛9的Stobbe缩合，以及中间体2,3-二取代戊二醛在C-4处的羟基化。酯14。

  DOI：

  10.1016/0040-4020(95)00836-w

文献信息

• Lignanes. 18. Synthèse Totale et Confirmation de la Structure de l'Acide Mégacérotonique
  作者：Eric Brown、Robert Dhal、Nadine Papin

  DOI：10.1016/0040-4020(95)00836-w

  日期：1995.11

  Megacerotonic acid 1 has a highly exceptional structure, since it is probably the only γ-butyrolactone lignan in which the lactone ring is substituted by an aryl, an arylidene and a carboxy group. The structure of this lignan was confirmed by a racemic total synthesis which involved as key-steps a Stobbe condensation of the 3-arylglutaric ester 8 with p-anisaldehyde 9, and the hydroxylation at C-4

  大cetrooniconic acid 1具有非常优异的结构，因为它可能是唯一的内酯环被芳基，亚芳基和羧基取代的γ-丁内酯木脂素。该木脂素的结构通过外消旋的全合成得到证实，该合成涉及作为关键步骤的3-芳基戊二酸酯8与对茴香醛9的Stobbe缩合，以及中间体2,3-二取代戊二醛在C-4处的羟基化。酯14。
• Heteroarylakanoic acids as intergrin receptor antagonists
  申请人：——

  公开号：US20040092497A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the &agr;&ngr;&bgr; 3 and/or the &agr;&ngr;&bgr; 5 integrin without significantly antagonizing the IIb/IIIa integrin. 1

  本发明涉及一类由式（I）表示的化合物或其药学上可接受的盐、包含式（I）化合物的制药组合物以及选择性拮抗&agr;&ngr;&bgr;3和/或&agr;&ngr;&bgr;5整合素而不显著拮抗IIb/IIIa整合素的方法。
• Heteroarylalkanoic acids as integrin receptor antagonists derivatives
  申请人：Boys L. Mark

  公开号：US20050043344A1

  公开（公告）日：2005-02-24

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the α V β 3 and/or the α V β 5 integrin without significantly inhibiting the α V β 6 integrin.

  本发明涉及包含式I的化合物或其药学上可接受的盐的制药组合物，以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法，而不显著抑制αVβ6整合素。
• Heteroarylalkanoic acids as integrin receptor antagonists
  申请人：——

  公开号：US20020133023A1

  公开（公告）日：2002-09-19

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively antagonizing the &agr; V &bgr; 3 and/or the &agr; V &bgr; 5 integrin without significantly antagonizing the IIb/IIIa or &agr; V &bgr; 6 integrin.

  本发明涉及一类由式I1表示的化合物或其药学上可接受的盐，包括式I的药物组合物，并且涉及一种选择性拮抗&agr;V&bgr;3和/或&agr;V&bgr;5整合素而不显著拮抗IIb/IIIa或&agr;V&bgr;6整合素的方法。
• The Synthesis of Substituted β-Thienyl- and β-Furylglutaric Acids
  作者：Walter T. Smith、Robert W. Shelton

  DOI：10.1021/ja01639a041

  日期：1954.5